Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | BID | P55957 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524582 | 0.99 | DNM1 (0.44) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2807791 | 0.91 | KCNH2 (0.37) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11128855 | 0.87 | THRA (0.44) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11659853 | 0.83 | MEN1 (0.43) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6662799 | 0.82 | KDM4E (0.36) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL25349713 | 0.81 | GABRA1 (0.35) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL56683 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL7650228 | 0.76 | THRA (0.49) | PPARAPPARGTHRATHRBALOX5 | |
| SCHEMBL8445975 | 0.76 | THRA (0.49) | PPARAPPARGTHRATHRBALOX5 | |
| SCHEMBL330345 | 0.76 | THRA (0.49) | PPARAPPARGTHRATHRBALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2023133143-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023091342-A1 | PRESERVATION SYSTEM FOR STABILIZING SPORE-FORMING MICROBIALS | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230151324-A1 | PRESERVATION SYSTEM FOR STABILIZING SPORE-FORMING MICROBIALS | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-05-18 | — | — | US | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| WO-2018204669-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2018-11-08 | — | — | WO | claimed |
| US-9492525-B2 | Human respiratory syncytial virus vaccine | NANOBIO CORPORATION (US) | 2016-11-15 | — | — | US | claimed |
| EP-2729169-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | Nanobio Corporation (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2545937-A1 | Nanoemulsion vaccines | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-16 | — | — | EP | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| EP-1411913-A4 | ANTIMICROBIAL NANOEMULSION COMPOSITIONS AND METHODS | UNIV MICHIGAN (US) | 2009-09-02 | — | — | EP | claimed |
| US-20090143476-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143477-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| WO-2008103416-A1 | SYNERGISTIC ENHANCEMENT OF CALCIUM PROPIONATE | CAPPS CHARLES L (US) | 2008-08-28 | — | — | WO | claimed |
| EP-1411913-A1 | ANTIMICROBIAL NANOEMULSION COMPOSITIONS AND METHODS | The Regents of the University of Michigan (US) | 2004-04-28 | — | — | EP | claimed |
| US-6559189-B2 | For decontaminating areas, samples, solutions, and foodstuffs colonized or infected by pathogens and microorganisms | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-05-06 | — | — | US | claimed |
| WO-2003000243-A1 | ANTIMICROBIAL NANOEMULSION COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020045667-A1 | Non-toxic antimicrobial compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | MEN1 624/4885KMT2A 2755/4885TP53 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.